Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research into the early detection of ovarian cancer by the Ahmed group at the MRC Weatherall Institute of Molecular Medicine (MRC WIMM) receives a boost thanks to a gift of £43,000 from the Dianne Oxberry Trust.

© Dr Siobhan Ferguson & Ian Hindle (Dianne Oxberry Trust), Prof Ahmed Ahmed, Abdulkhaliq Alsaadi & Mara Artibani (Weatherall Institute of Molecular Medicine, NDWRH, Oxford University)

The donation will support doctoral candidate Abdulkhaliq Alsaadi in this research by covering the stipend and other costs associated with his final year of study, including research consumables.

More than 250,000 women around the world are diagnosed with ovarian cancer every year, with almost half dying from the disease. This makes ovarian cancer the most common cause of death from a gynaecological malignancy. Late diagnosis a key contributing factor.

At Oxford, a concerted effort is being made to better understand the origins of the disease. Led by Ahmed Ahmed, Professor of Gynaecological Oncology in the Nuffield Department of Women’s and Reproductive Health, researchers are utilising cutting-edge methodologies to classify the cells in the fallopian tube – thought to be the organ from which most ovarian cancers develop. It is hoped that this will lead to the discovery of new biomarkers that could be used for pre-cancer screening.

Read more (MRC WIMM website)

Similar stories

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.